z-logo
open-access-imgOpen Access
Virtual Screening to Identify Protein Targets of Aggregatibacter Actinomycetemcomitans Interacting with Emodin
Author(s) -
R. Preety,
M. Jeevitha,
Vijayashree Priyadharsini Jayaseelan,
Selvaraj Jayaraman
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i62b35579
Subject(s) - aggregatibacter actinomycetemcomitans , virulence , emodin , virtual screening , microbiology and biotechnology , bacterial adhesin , biology , bacteria , computational biology , porphyromonas gingivalis , gene , biochemistry , genetics , drug discovery
Aim: The aim of the study is to identify protein targets of aggregatibacter actinomycetemcomitans interacting with emodin. Introduction: Aggregatibacter mycetemcomitans is a gram negative bacteria that is associated with localized chronic periodontitis and other systemic diseases. The organism produces a number of virulence factors which provides some benefits to the bacterium. In this study, protein targets of Aggregatibacter actinomycetemcomitans interacting with emodin were identified. Methodology: The present study follows an observational study design wherein we employed computational tools used to identify the targets, assess its functional role and virulence property. The protein targets in the bacteria were identified by virtual screening by using emodin as the compound. Results: Peptide epitopes present in the virulence factors were identified using the BepiPred tool. The subcellular location of the protein targets were elucidated using emodin as the phytocompound. The 3 - Deoxy - D - manno octulosonic acid, ArcB, hypothetical protein and Arabinose - 5 - phosphate isomerase were found to be virulent. Conclusion: Within the limits of this study, it provides substantial evidence on the protein targets acting against emodin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here